The Safety of Pharmacopuncture on Musculoskeletal Patients

Launched by JASENG MEDICAL FOUNDATION · Apr 1, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a treatment called pharmacopuncture for patients with musculoskeletal diseases, particularly those affecting the spine and joints. Pharmacopuncture combines acupuncture with herbal medicine, and the researchers want to see if there are any side effects after patients receive this treatment. The study is taking place in seven Korean medicine hospitals and aims to analyze blood tests and monitor any adverse events that may occur during the treatment.

To be eligible for this trial, participants need to be hospitalized patients aged 19 to 69 who have a diagnosed spinal joint disease and are willing to participate by giving written consent. Those who have trouble understanding the study or cannot provide consent may not be eligible. If you choose to participate, you will receive pharmacopuncture treatment and help researchers learn more about its safety for future patients. Your involvement will contribute to our understanding of this therapeutic approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inpatients with diagnosed spinal joint disease
• • Patients who received pharmacopuncture treatment during hospitalization
• • Patients who are 19 years of age or older and less than 70 years old
• • Patients who agreed to participate in the clinical study and voluntarily given written informed consent
• Exclusion Criteria:
• • Patients with difficulty or refusal to give sign written informed consent
• • Patients for whom the researchers judge participation in the clinical study to be difficult